Quince Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2019 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Quince Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2019 to Q2 2024.
  • Quince Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 89.2 %, a 2401% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 89.2 +85.6 +2401% Jun 30, 2024
Q1 2024 52.3 +47.9 +1081% Mar 31, 2024
Q4 2023 26.1 +20.3 +348% Dec 31, 2023
Q3 2023 2.95 -5.21 -63.9% Sep 30, 2023
Q2 2023 3.57 -6.13 -63.2% Jun 30, 2023
Q1 2023 4.43 -7.27 -62.1% Mar 31, 2023
Q4 2022 5.83 -6.32 -52.1% Dec 31, 2022
Q3 2022 8.16 -3.33 -29% Sep 30, 2022
Q2 2022 9.7 -1.11 -10.3% Jun 30, 2022
Q1 2022 11.7 +2.61 +28.7% Mar 31, 2022
Q4 2021 12.1 +4.39 +56.6% Dec 31, 2021
Q3 2021 11.5 +4.27 +59.2% Sep 30, 2021
Q2 2021 10.8 +4.52 +71.8% Jun 30, 2021
Q1 2021 9.09 +3.19 +54.1% Mar 31, 2021
Q4 2020 7.75 -0.03 -0.39% Dec 31, 2020
Q3 2020 7.21 -2.69 -27.2% Sep 30, 2020
Q2 2020 6.29 Jun 30, 2020
Q1 2020 5.9 Mar 31, 2020
Q4 2019 7.78 Dec 31, 2019
Q3 2019 9.9 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.